

Atty. Dkt. No. P63132US0
Serial No.: 09/171,607

Deu-Lys-Pro-Gly-Ala-Arg-Ile-Phe-Ser-Phe-Asp-Gly-Lys-Asp-Val-Leu-Arg-His-Pro-Thr-
Trp-Pro-Gln-Lys-Ser-Val-Trp-His-Gly-Ser-Asp-Pro-Asn-Gly-Arg-Arg-Leu-Thr-Glu-Ser-
Tyr-Cys-Glu-Thr-Trp-Arg-Thr-Glu-Ala-Pro-Ser-Ala-Thr-Gly-Gln-Ala-Ser-Ser-Leu-Leu-Gly-
Gly-Arg-Leu-Leu-Gly-Gln-Ser-Ala-Ala-Ser-Cys-His-His-Ala-Tyr-Ile-Val-Leu-Cys-Ile-Glu-
Asn-Ser-Phe-Met-Thr-Ala-Ser (HF-COLL-18/514cf) (SEQ ID NO: 1).

- C1
44. An amidated, acetylated, phosphorylated, or glycosylated derivative of the peptide of claim 43.
45. A process for the preparation of the peptide according to claim 43 and/or its amidated, acetylated, phosphorylated, or glycosylated derivative through prokaryotic or eukaryotic expression.
46. A process for the preparation of the peptide according to claim 43 and/or its amidated, acetylated, phosphorylated, or glycosylated derivative through isolation from human blood using chromatographic methods.
47. A process for the preparation of the peptide according to claim 43 and/or its amidated, acetylated, phosphorylated, or glycosylated derivative by solid-phase and liquid-phase synthesis and purification by chromatographical methods.
48. A medicament containing the peptide according to claim 43 or its amidated, acetylated, phosphorylated, or glycosylated derivative as the active ingredient in combination with excipients.

Atty. Dkt. No. P63132US0
Serial No.: 09/171,607

- C1
49. Medicament according to claim 48 for oral, parenteral, intravenous, intramuscular, intracutaneous, intrathecal, intranasal or local-topical application or in the form of an aerosol for transpulmonary application.
50. Antibodies obtainable by immunizing animals with the peptide according to claim 43 and/or its amidated, acetylated, phosphorylated, and glycosylated derivative, or obtainable by using hybridoma technology.
51. A method for the treatment of patients in need of HF-COLL-18/514cf by the administration of therapeutic amounts of HF-COLL-18/514cf or its derivative according to claim 44.
52. A method for the treatment of patients in need of an inhibition of HF-COLL-18/514cf by the administration of therapeutic amounts of an antagonist/inhibitor of HF-COLL-18/514cf or an antagonist/inhibitor of its derivative according to claim 44.
53. Method of using the medicament according to claim 48 by administration to a human patient for the treatment of diseases in connection with capillary proliferations.
54. Method of using the medicament according to claim 48 by administration to a human patient for the treatment of carcinoses.
55. Method of using the medicament according to claim 48 by administration to a human patient for the treatment of diseases involving the cardiovascular and nervous systems.
56. Method of using the medicament according to claim 48 by administration to a human patient for the treatment of diseases involving the integument and the sense organs.

Atty. Dkt. No. P63132US0

Serial No.: 09/171,607

- C1
57. Method of using the peptide according to claim 43, its amidated, acetylated, phosphorylated, or glycosylated derivative, or antibodies obtainable by immunizing an animal with said peptide and/or its amidated, acetylated, phosphorylated, or glycosylated derivative or obtainable by using hybridoma technology by formulation as a medicament for the treatment of disorders in inflammatory processes, disturbed inflammatory reactions, proliferation and maturation disorders of the blood-forming system.
58. Method of using the medicament according to claim 48 or antibodies obtainable by immunizing an animal with said peptide and/or its amidated, acetylated, phosphorylated, or glycosylated derivative or obtainable by using hybridoma technology by administration to a human patient for the treatment of systemic diseases resulting from overproduction or deficiency of HF-COLL-18/514cf.
59. Method of using the medicament according to claim 48 or antibodies obtainable by immunizing an animal with said peptide and/or its amidated, acetylated, phosphorylated, or glycosylated derivative or obtainable by using hybridoma technology by administration to a human patient for the treatment of tumor and vascular diseases.
60. Method of using the medicament according to claim 48 or antibodies obtainable by immunizing an animal with said peptide and/or its amidated, acetylated, phosphorylated, or glycosylated derivative or obtainable by using hybridoma technology by administration to a human patient for the treatment of acute diseases in intensive care.